TherapeuticsMD (TXMD) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
TherapeuticsMD (TXMD) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | TherapeuticsMD | 23.54 Mn | 14.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 81.60% |
| Mar 31, 2026 | 81.74% |
| Dec 31, 2025 | 82.45% |
| Sep 30, 2025 | 14.91% |
| Jun 30, 2025 | 14.87% |
| Mar 31, 2025 | 80.27% |
| Dec 31, 2024 | 14.90% |
| Sep 30, 2024 | 73.47% |
| Jun 30, 2024 | 76.45% |
| Mar 31, 2024 | 14.89% |
| Dec 31, 2023 | 15.06% |
| Sep 30, 2023 | 44.10% |
| Mar 31, 2023 | 44.43% |
| Dec 31, 2022 | 27.47% |
| Sep 30, 2022 | 0.46% |
| Jun 30, 2022 | 53.28% |
| Mar 31, 2022 | -8.04% |
| Dec 31, 2021 | 33.22% |
| Sep 30, 2021 | -13.64% |
| Jun 30, 2021 | -15.12% |